E-LIB Suche - Ergebnisse für: Flaig, T.

1

PCR53 Patient Experiences Before and After Enfortumab Vedot..:

Flaig, T ; Hepp, Z ; Narayanan, S...
Value in Health. 25 (2022) 12 - p. S400 , 2022

Link: https://doi.org/10.1016/..

2

EV-103 Study: A phase 1b dose-escalation and dose-expansion..:

Hoimes, C.J. ; Petrylak, D. ; Flaig, T....
European Urology Supplements. 17 (2018) 2 - p. e1151 , 2018

Link: https://doi.org/10.1016/..

3

Tocilizumab-induced pancreatitis: case report and review of..:

Flaig, T. ; Douros, A. ; Bronder, E....
Journal of Clinical Pharmacy and Therapeutics. 41 (2016) 6 - p. 718-721 , 2016

Link: https://doi.org/10.1111/..

4

864 Does Gleason score at initial diagnosis predict efficac..:

Stöckle, M. ; Flaig, T. ; Ohlmann, C.H....
European Urology Supplements. 13 (2014) 1 - p. e864-e864a , 2014

Link: https://doi.org/10.1016/..

5

ASCO leadership development group – geriatric oncology focu..:

Flaig, T.
Journal of Geriatric Oncology. 4 (2013) - p. S11 , 2013

Link: https://doi.org/10.1016/..

6

Stereotactic Body Radiation Therapy for Melanoma and Renal ..:

Stinauer, M.A. ; Kavanagh, B. ; Schefter, T....
International Journal of Radiation Oncology*Biology*Physics. 78 (2010) 3 - p. S190-S191 , 2010

Link: https://doi.org/10.1016/..

7

Corrections to Final overall survival analysis for the phas..:

Knox, J.J. ; Barrios, C.H. ; Kim, T.M....
Annals of Oncology. 29 (2018) 11 - p. 2269 , 2018

Link: https://doi.org/10.1093/..

8

Final overall survival analysis for the phase II RECORD-3 s..:

Knox, J.J. ; Barrios, C.H. ; Kim, T.M....
Annals of Oncology. 28 (2017) 6 - p. 1339-1345 , 2017

Link: https://doi.org/10.1093/..

9

Organ Preservation for Muscle-Invasive Squamous Cell Carcin..:

Stokes, W.A. ; Kessler, E.R. ; Wilson, S....
International Journal of Radiation Oncology*Biology*Physics. 99 (2017) 2 - p. E266 , 2017

Link: https://doi.org/10.1016/..

10

Proton Beam Therapy Utilization and Disparity in the United..:

Amini, A. ; Kavanagh, B.D. ; Raben, D....
International Journal of Radiation Oncology*Biology*Physics. 96 (2016) 2 - p. E244-E245 , 2016

Link: https://doi.org/10.1016/..

11

556 Abiraterone acetate improves overall survival in chemot..:

Mulders, P.F.A. ; Smith, M.R. ; Fizazi, K....
European Urology Supplements. 14 (2015) 2 - p. e556-e556a , 2015

Link: https://doi.org/10.1016/..

12

863 Low dose GTx-758 decreases free testosterone to levels ..:

Getzenberg, R.H. ; Yu, E.Y. ; Smith, J.A....
European Urology Supplements. 13 (2014) 1 - p. e863 , 2014

Link: https://doi.org/10.1016/..

13

105 Exploratory analysis of the visceral disease patient su..:

Suttmann, H. ; Mulders, P.F.A. ; Molina, A....
European Urology Supplements. 12 (2013) 1 - p. e105-e106 , 2013

Link: https://doi.org/10.1016/..

14

A phase I study of sorafenib and vorinostat in patients wit..:

Dasari, A. ; Gore, L. ; Messersmith, W. A....
Investigational New Drugs. 31 (2012) 1 - p. 115-125 , 2012

Link: https://doi.org/10.1007/..

15

204 POSTER Recombinant IL-21 in combination with sorafenib ..:

Flaig, T.W. ; Curti, B.D. ; Gordon, M.S....
European Journal of Cancer Supplements. 6 (2008) 12 - p. 64-65 , 2008

Link: https://doi.org/10.1016/..